A novel therapeutic option for HER2-positive extramammary Paget disease

The research article presents a comprehensive evaluation of the human epidermal growth factor receptor 2 (HER2) status in extramammary Paget disease (EMPD) and explores the therapeutic potential of disitamab vedotin (DV), a novel humanized anti-HER2 antibody-drug conjugate (ADC), for this rare adenocarcinoma.

J&J and Legend’s Carvykti scores early line approval for MM by FDA

Share this article J&J and Legend Biotech’s Carvykti is a B-cell maturation antigen (BCMA) directed CAR-T cell therapy. Image Credit: Corona Borealis Studio / Shutterstock.

April 8, 2024

WellSky Taps Google Cloud to Build Gen AI Tools for Providers

What You Should Know: – WellSky, a health and community care technology company, and Google Cloud have announced a strategic partnership to leverage cutting-edge cloud

February 2, 2024

Study reveals molecular mechanism behind new DOT1L-related disorder

A study from the laboratory of Dr. Hugo J. Bellen, a distinguished service professor at Baylor College of Medicine and a principal investigator at the

October 14, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.